Vivos Therapeutics Inc Total Liabilities
Vivos Therapeutics Inc total liabilities. Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has total liabilities worth $28.13 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See VVOS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Vivos Therapeutics Inc (2018–2025)
Total liabilities of Vivos Therapeutics Inc from 2018 to 2025. This chart illustrates how Vivos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Vivos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Vivos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Realites
PA:ALREA
|
France | €899.21 Million |
|
Merko Gida Sanayi ve Ticaret AS
IS:MERKO
|
Turkey | TL953.48 Million |
|
Young & Co.'s Brewery P.L.C
LSE:YNGN
|
UK | GBX525.90 Million |
|
Uscom Ltd
AU:UCM
|
Australia | AU$278.09K |
|
Silly Monks Entertainment Limited
NSE:SILLYMONKS
|
India | Rs26.20 Million |
|
Grand Gulf Energy Ltd
AU:GGE
|
Australia | AU$706.41K |
|
Parabellum Resources Ltd
AU:PBL
|
Australia | AU$63.51K |
Liability Composition Analysis (2018–2025)
This chart breaks down Vivos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Vivos Therapeutics Inc.
Liquidity & Leverage Metrics
Vivos Therapeutics Inc Total Liabilities Ratios Explained
Vivos Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vivos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Vivos Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.70 Million | +264.28% |
| 2024-12-31 | $7.33 Million | -28.97% |
| 2023-12-31 | $10.32 Million | +15.70% |
| 2022-12-31 | $8.92 Million | +9.44% |
| 2021-12-31 | $8.15 Million | -3.09% |
| 2020-12-31 | $8.41 Million | -19.86% |
| 2019-12-31 | $10.49 Million | +210.75% |
| 2018-12-31 | $3.38 Million | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more